ClinicalTrials.gg
RecruitingNCT06570317Updated Aug 26, 2024

Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

An observational study in NSCLC, Nintedanib and Radiation Pneumonitis, sponsored by Second Hospital of Shanxi Medical University. Recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Second Hospital of Shanxi Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Radiation Pneumonitis with a site in China — 9 open to participants now, 11 under way, none of them phase 3. Radiation Pneumonitis · China.

Started
2024
with 3 others
Observational
6 of 16
4 open now
Primary completion
2026-05
later than 5 of 10 live
Registered
9th of 16
by date
Lead sponsor
1 of 16
Second Hospital of Shanxi Medical University

Among the 16 studies in Radiation Pneumonitis with a site in China, this one is one of 4 that started in 2024, is one of 6 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 9th registered.

Radiation Pneumonitis

40 studies on the registry are indexed under Radiation Pneumonitis; 17 are open to participants now.

Browse Radiation Pneumonitis studies →

Open to participants now

9 of the 16 studies in Radiation Pneumonitis with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Radiation Pneumonitis studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Radiation Pneumonitis with a site in China, or all of them as a file.
02

Study summary

This study is aimed at patients with unresectable NSCLC who take nintedanib during sequential radiotherapy to explore the incidence of radiation pneumonitis above grade 2 in the nintedanib combined with radiotherapy mode and observe safety. And will further explore the progression-free survival (PFS) and overall survival (OS) of patients treated with nintedanib in combination with radiotherapy and immunotherapy.

Primary objective: To evaluate the safety of nintedanib combined with sequential radiotherapy in patients with unresectable NSCLC and the incidence of radiation pneumonitis above grade 2. Secondary objective: To evaluate the changes in lung function, progression-free survival (PFS) and overall survival (OS) in patients with unresectable NSCLC after nintedanib combined with sequential radiotherapy.

Patients need to receive induction therapy, chemotherapy and/or immunotherapy for at least one cycle. Then they will receive sequential radiotherapy and nintedanib for 6 months. Finally, they will receive immunotherapy maintenance therapy for 16 cycles.

03

Conditions studied

  • NSCLC
  • Nintedanib
  • Radiation Pneumonitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

men or women over the age of 18 (including 18 years old), whose vital organs function well, who are diagnosed as non-small cell lung cancer by histology and cannot be surgically removed, and whose EGFR/ALK driver gene is negative by gene mutation test. The score of physical fitness in the Eastern Cooperative Oncology Group (ECOG) is 0 \~ 1, and the life expectancy is ≥3 months. At least one measurable lesion (non-brain) according to RECISTv1.1.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Men or women who are over 18 years old (including 18 years old) when signing the form;
    1. Non-small cell lung cancer was confirmed by histology and could not be resected, and EGFR/ALK driver gene was confirmed negative by gene mutation examination;
    1. At least one with imaging examination (according to RECIST1.1) is examined by spiral CT or MR, and the length and diameter of the lesion are ≥ 10 mm;
    1. within 3 days before treatment, the score according to is 0 \~ 1;
    1. ≥3 months;
  • 6)The vital organs function well,
  • 7)The subjects volunteered to join the study and signed the informed consent form, with good compliance and cooperation with the follow-up.

Exclusion criteria

Exclusion Criteria:

    1. Complicated with severe respiratory diseases: pulmonary fibrosis, active tuberculosis, etc.
  • 2)Persons with mental disorder, blood system diseases, diseases and serious primary diseases of heart, brain, liver and kidney;
    1. Hemorrhagic events that require blood transfusion, invasive intervention or hospitalization occur within 3 months before the first administration, or there are bleeding symptoms and need intervention treatment (such as hemoptysis, hematuria and bloody stool), or high-risk factors with bleeding risk (such as tumor surrounding or invading important blood vessels, obvious necrosis or cavity around tumor, esophageal varices, etc.);
    1. Thrombosis or embolic diseases, abnormal blood coagulation function and bleeding tendency;
    1. Known or suspected to be allergic to the study drug and its auxiliary materials;
    1. The baseline pregnancy test of pregnant and lactating women or fertile women is positive.
    1. According to the researcher's judgment, the subjects have other factors that may lead to the forced termination of this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Interventions

  • For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy

06

What researchers measure

Primary outcomes

  1. security

    Incidence of adverse events

    Time frame: Up to 2 years

  2. Incidence rate of radiation pneumonia

    Incidence of grade 2 and above radiation pneumonia

    Time frame: Up to 2 years

Secondary outcomes

  1. Pulmonary function index

    Changes of pulmonary function indexes(FEV1, Dlco)

    Time frame: Up to 2 years

  2. Progression-free Survival (PFS)

    From the date of enrollment to the date of disease progression

    Time frame: Up to 2 years

  3. Overall Survival (OS)

    From the date of enrollment until death by any cause or last follow-up

    Time frame: Up to 2 years

07

Study locations

7 of 7 sites recruiting
  • Jincheng General Hospital
    Jincheng, Shanxi, China
    Recruiting
    • Xueqin Li, Dr. · Contact+86 356 3661360
  • Jinzhong third people's hospital
    Jinzhong, Shanxi, China
    Recruiting
    • Qian Wu, Dr. · Contact+86 354 3532157
  • Frist Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
    Recruiting
    • Dongwen Rong, Dr. · Contact+86 13803491151
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
    Recruiting
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
    Recruiting
    • Huijing Feng, Dr. · Contact+86 351 8368114
  • Shanxi Hospital of Traditional Chinese Medicine
    Taiyuan, Shanxi, China
    Recruiting
    • Jinyang Bai, Dr. · Contact+86 351 303009
  • TISCO General Hospital
    Taiyuan, Shanxi, China
    Recruiting
    • Weihua Jia, Dr. · Contact+86 351 3012448
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for May 2026, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 26, 2024
StartEst.
Aug 24, 2024
Primary completionEst.
May 31, 2026
CompletionEst.
Jun 30, 2026
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570317
Lead sponsor
Second Hospital of Shanxi Medical University
Responsible party
Gang Jin (Director, Second Hospital of Shanxi Medical University) — Principal investigator
First posted
Aug 26, 2024
Start date
Aug 24, 2024 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 26, 2024

Study contacts

Gang Jin, Dr.
Contact
jingang2018@sina.com
+86 351 3365422
Chen Zhang
Contact
+86 351 3365422
Gang Jin, Dr.
principal investigator · Second Hospital of Shanxi Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion